Product Development and Clinical Trials - MICVO, the lead product candidate, is an investigational ADC targeting EDB+FN, which is highly expressed in tumors but minimally in normal tissues[18]. - In the Phase 1 monotherapy study, MICVO showed a 50% confirmed objective response rate (ORR) in heavily pre-treated patients with R/M HNSCC at a dose of 3.6 mg/kg to 5.4 mg/kg[21]. - The ongoing dose expansion phase of the monotherapy study aims to evaluate MICVO at 5.4 mg/kg IV Q3W, with a target enrollment of approximately 40 patients[29]. - Preliminary data from the combination study with KEYTRUDA® indicated a 71% confirmed ORR among seven efficacy-evaluable patients with 1L/2L+ R/M HNSCC[26]. - The disease control rate (DCR) for MICVO monotherapy in R/M HNSCC was reported at 92% among 13 efficacy evaluable patients[23]. - The company plans to report updated clinical data from the monotherapy and combination studies in mid-2026 and the second half of 2026, respectively[28][32]. - The Phase 1/2 combination study with KEYTRUDA® is designed to evaluate safety, tolerability, and preliminary efficacy across multiple tumor types[25]. - MICVO was generally well tolerated, with no Grade 4 or Grade 5 treatment-related adverse events reported, and 89% of patients experienced treatment-related adverse events[24]. - The company is actively exploring dosing modifications to optimize MICVO's benefit-risk profile, particularly for patients with higher body weight[24]. - The confirmed overall response rate (ORR) for MICVO monotherapy in patients with R/M HNSCC was 46% (6/13), with a disease control rate (DCR) of 92% (12/13) as of the November 3, 2025 data cut-off[97]. - Among the seven response-evaluable patients in the combination study with pembrolizumab, the confirmed ORR was 71% (5/7) per RECIST v1.1[128]. - Treatment-related adverse events (TRAEs) were reported in 89% (16/18) of patients treated with MICVO, with 56% (10/18) experiencing Grade 3 or higher TRAEs[102]. - The ongoing study has implemented modified dosing strategies for MICVO, including dose capping and AIBW-based dosing, to improve tolerability in higher body weight patients[106]. - The Phase 1 study of PYX-106 enrolled 45 patients, with 41 evaluable, and was observed to be generally safe and well-tolerated across doses from 0.5 mg/kg to 22.5 mg/kg[138]. - PYX-107 demonstrated a 15.2% partial response rate and a 30.3% stable disease rate in melanoma patients refractory to anti-PD-(L)1 in a Phase II trial[139]. Market Need and Competitive Landscape - Head and neck cancer is projected to reach approximately one million new cases annually by 2030, highlighting the unmet medical need in this area[35]. - The company is prioritizing the development of its lead product candidate, MICVO, for R/M HNSCC, addressing a significant unmet need with an estimated one million new cases globally by 2030[37]. - Approximately 60,000 cases of HNSCC are diagnosed annually in the U.S., with a 13% 5-year survival rate in the R/M setting, highlighting the urgent need for effective therapies[36]. - The median overall survival for patients with 1L R/M HNSCC ranges from 9 months (HPV unrelated) to about 14 months (HPV+)[36]. - The overall incidence of HNSCC is expected to rise by 30% annually by 2030, driven by factors such as tobacco use and HPV infections[36]. - Emerging therapies targeting EDB+FN, such as MICVO, are designed to improve anti-tumor activity and stability compared to conventional ADCs[47]. - Competition includes various companies developing cancer immunotherapies and ADCs, which may impact the company's ability to execute its business plan[150]. - Emerging agents targeting R/M HNSCC, such as Genmab's and Johnson & Johnson's products, pose significant threats to the company's clinical development strategy[154]. Intellectual Property and Licensing - The company aims to maximize value from its intellectual property and technology platforms, including the Flexible Antibody Conjugation Technology (FACT) platform for ADC development[37]. - The company has a patent portfolio comprising 29 different patent families, including patents licensed from the University of Chicago, Pfizer, and Biosion[200]. - The patent family for MICVO includes granted patents and pending applications with expiration dates ranging from 2032 to 2046[202]. - The company has sole ownership of a patent family for dosage and treatment regimens of MICVO, with a pending PCT application expiring in 2045[208]. - The company has joint ownership of a patent family for the combination of MICVO and pembrolizumab, with a term running through 2046[210]. - The company is focused on protecting its intellectual property through patent protection and trade secrets, which are critical to its business[194]. - The company has exclusively licensed a patent family from Pfizer related to cytotoxic pentapeptides and antibody-drug conjugates, with patents granted in multiple countries including the United States, and a 20-year term running through 2032[211]. - A patent family for antibodies and antibody fragments for site-specific conjugation has been exclusively licensed from Pfizer, with a 20-year term running through 2036 and patents granted in several countries including Canada and Australia[212]. - The company has licensed a patent family for engineered antibody constant regions for site-specific conjugation from Pfizer, with patents granted in the United States and a 20-year term running through 2032[213]. - A patent family for PYX-203, an anti-CD123 antibody-drug conjugate, has been exclusively licensed from Pfizer, with patents granted in the United States and a 20-year term running through 2038[214]. - The company has licensed a patent family for PYX-106, an anti-Siglec-15 antibody, from Biosion USA, Inc., with patents granted in the United States and a 20-year term running through 2041[215]. - Through the acquisition of Apexigen, Inc., the company has acquired two patent families for high affinity CD40 agonist monoclonal antibodies, with the first family having a 20-year term running through 2032 and patents granted in the United States[216]. - The second patent family for CD40 agonist antibodies includes patents granted in the United States and a 20-year term running through 2033[216]. Financial and Operational Considerations - The company has entered into multiple licensing agreements, including a $25 million agreement with Pfizer for ADC product candidates, which includes an upfront cash payment of $5 million and shares valued at $20 million[171]. - The company is obligated to pay Pfizer up to $665 million in future contingent payments for the first four licensed ADCs, along with tiered royalties on net sales ranging from low single digits to mid-teens[174]. - Under the Biosion License Agreement, the company paid an upfront fee of $10 million and is obligated to pay up to $217.5 million in future contingent payments for normal approval, with royalties on net sales ranging from low single digits to low teens[178]. - The company currently has no sales, marketing, or commercial product distribution capabilities but plans to build a specialized sales and marketing organization over time[165]. - The company relies on third-party contract development and manufacturing organizations (CDMOs) for the manufacture of its product candidates, limiting direct control over manufacturing capacity and compliance[159]. - The company has established internal personnel and governance processes to oversee CDMOs and manage manufacturing data and regulatory documentation[164]. - The company is obligated to use commercially reasonable efforts to develop and bring licensed products to market, including meeting specific preclinical and clinical development milestones[169]. - The company has no plans to establish its own cGMP-compliant manufacturing facilities and will continue to rely on third-party manufacturers[159]. - The company assessed milestone and royalty events under the University License Agreement and determined that no amounts were required as of December 31, 2025 and 2024[168]. - The company is dependent on the performance and compliance of its CDMOs, and any failure could materially affect development timelines and commercialization efforts[160]. - In August 2023, the company completed the acquisition of Apexigen, which is now a wholly owned subsidiary, and assumed all out-licensing agreements of Apexigen[181]. - The company received a $3 million regulatory approval milestone under the Simcere Agreement upon the approval of suvemcitug by the NMPA in June 2025[186]. - In December 2025, the company relinquished future royalties on net sales of Enzeshu® to Simcere for a one-time payment of $11 million and four semi-annual installments of $175,000 each[187].

Core Insights - Pyxis Oncology has completed target enrollment in the Phase 1 monotherapy dose expansion study of micvotabart pelidotin (MICVO) for 2L+ recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) in Q1 2026, with updated data expected mid-2026 [1][5] - The company has appointed Thomas Civik as Interim Chief Executive Officer, focusing on clinical execution and operations to deliver robust datasets [3][6] - Financial results for the year ended December 31, 2025, show revenues of $13.9 million, a decrease from $16.1 million in 2024, with a net loss of $79.6 million [8][10] Clinical Development Updates - The Phase 1 monotherapy study of MICVO in 2L+ R/M HNSCC reported a 46% confirmed objective response rate (ORR) and a 92% disease control rate (DCR) [4] - In combination with KEYTRUDA, MICVO showed a 71% confirmed ORR and a 100% DCR in 1L/2L+ R/M HNSCC [4] - The ongoing studies are designed to evaluate the impact of modified weight-based dosing on safety and efficacy, with results anticipated in mid-2026 [7][11] Financial Performance - Total revenues for 2025 were $13.9 million, down from $16.1 million in 2024, primarily due to changes in milestone revenues and royalty rights [10][15] - Research and development expenses increased to $73.7 million in 2025 from $58.7 million in 2024, attributed to higher clinical trial costs [10][16] - The company reported a net loss of $79.6 million for 2025, slightly higher than the $77.3 million loss in 2024 [10][16] Leadership and Corporate Updates - Thomas Civik was appointed as Interim CEO in February 2026, bringing extensive experience in advancing cancer therapeutics [6][10] - Heather Knowles joined as Senior Vice President, Head of Global Clinical Operations, enhancing the company's clinical development capabilities [10] - The company has also appointed Alex Kane as Senior Vice President, Investor Relations and Capital Markets, to strengthen investor engagement [10] Pipeline and Future Outlook - Pyxis Oncology expects to report updated data from the ongoing MICVO Phase 1/2 combination study with KEYTRUDA in the second half of 2026 [7][11] - The company has received Fast Track Designation from the FDA for MICVO in treating adult patients with R/M HNSCC [12]

Core Viewpoint - Pyxis Oncology, Inc. is undergoing a leadership transition with the appointment of Thomas Civik as Interim CEO, following the departure of Lara S. Sullivan, to ensure continuity in advancing the company's strategic and clinical goals [1][2][3]. Leadership Transition - Thomas Civik, a long-time member of the Board of Directors and an experienced biotechnology executive, has been appointed as Interim Chief Executive Officer [2][4]. - Lara S. Sullivan has stepped down from her roles as President, CEO, and Chief Medical Officer after six years of leadership [2][4]. - The Board of Directors is conducting a structured search for a permanent CEO while maintaining operational continuity through the established clinical development leadership team [3][4]. Company Focus and Clinical Programs - Pyxis Oncology's lead program, micvotabart pelidotin (MICVO), is currently in a Phase 1 monotherapy study for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) and a Phase 1/2 study in combination with Merck's pembrolizumab [4][8]. - The company aims to prioritize the execution of its clinical programs and upcoming milestones, focusing on improving patient outcomes in difficult-to-treat cancers [5][8]. Background of Interim CEO - Thomas Civik previously served as President and CEO of Five Prime Therapeutics, leading its acquisition by Amgen for $1.9 billion in April 2021 [5][6]. - He has extensive experience in oncology development, having held leadership roles at Genentech for 17 years, overseeing key therapies such as Avastin and Tecentriq [6]. About Pyxis Oncology - Pyxis Oncology is a clinical-stage biopharmaceutical company focused on developing therapeutics for difficult-to-treat cancers, with MICVO being a first-in-concept antibody-drug conjugate targeting extradomain-B of fibronectin [7][10]. - MICVO is designed to treat solid tumors through a multi-pronged mechanism of action, including direct tumor cell killing and mobilizing an anti-tumor immune response [10].

Core Insights - Pyxis Oncology Inc. has released preliminary data from its ongoing Phase 1 studies of micvotabart pelidotin (MICVO) for recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [1][5] Group 1: Study Results - In the monotherapy cohort, the confirmed overall response rate was 46% (6 of 13 patients), with a disease control rate of 92% (12 of 13 patients) [3] - The combination therapy cohort showed a confirmed overall response rate of 71% (5 of 7 patients) and a disease control rate of 100% (7 of 7 patients) [4] Group 2: Tolerability and Safety - MICVO was generally well tolerated, with no Grade 4 or Grade 5 treatment-related adverse events reported [4] - There was a noted 28% discontinuation rate in the study, which is significantly higher than the typical 10%-15% seen in oncology trials [7] Group 3: Future Plans - Pyxis Oncology plans to present updated data from the Phase 1 monotherapy study in mid-2026 and from the Phase 1/2 study in the second half of 2026 [5] - The company is evaluating the path forward for pivotal studies of MICVO as both a monotherapy and in combination with pembrolizumab [5] Group 4: Financial Update - Pyxis Oncology completed the sale of its rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11 million, which will support the development of MICVO [6] - The current cash runway is expected to fund operations through data milestones and into the fourth quarter of 2026 [6] Group 5: Market Reaction - Following the data release, Pyxis Oncology shares closed down about 49% at $1.73, reflecting concerns over limited data interpretability and tolerability issues [7] - Analysts have reiterated a Market Perform rating on Pyxis shares due to uncertainties regarding efficacy and the small sample size of the studies [9]

Core Viewpoint - Pyxis Oncology is conducting a clinical update call regarding its MICVO treatment for recurrent metastatic head and neck squamous cell carcinoma, indicating ongoing developments in its clinical research efforts [2]. Group 1: Company Overview - Alex Kane serves as the Senior Vice President of Investor Relations and Capital Markets at Pyxis Oncology, leading the discussion on the clinical update [2]. - The call will feature remarks from Lara Sullivan, the President, CEO, and CMO of Pyxis Oncology, followed by a Q&A session with her and other team members [2]. Group 2: Clinical Update - The focus of the call is on the clinical update for MICVO, specifically targeting recurrent metastatic head and neck squamous cell carcinoma, highlighting the company's commitment to advancing its oncology pipeline [2].

Summary of Pyxis Oncology Clinical Update Call Company Overview - **Company**: Pyxis Oncology (NasdaqGS:PYXS) - **Focus**: Development of MCVO for treating Recurrent Metastatic Head and Neck Squamous Cell Carcinoma Key Points from the Call Clinical Data Updates - **Monotherapy Results**: - Confirmed objective response rate (ORR) of **46%** and disease control rate (DCR) of **92%** in a cohort of **13 patients** at a dose of **5.4 mg/kg** [4][20] - Initial data indicates rapid tumor regression and durability of response [4] - **Combination Therapy with Pembro**: - Achieved a **71%** confirmed ORR and **100%** DCR in a cohort of **7 patients** at doses of **3.6 mg/kg** and **4.4 mg/kg** [5][37] - Ongoing evaluation of the **5.4 mg/kg** dose in combination therapy [5] Mechanism of Action - **MCVO**: A first-in-concept extracellular targeting antibody-drug conjugate (ADC) that targets EDB plus FN, a variant of fibronectin associated with tumor growth [6][10] - **Mechanism**: - Payload cleaves in the tumor microenvironment, diffusing into tumor cells and triggering bystander effects [10] - Activates T cells, enhancing immune response against tumors [10] Market Analysis - **Head and Neck Cancer Market**: - The sixth largest oncology market with limited competition and significant opportunities for new therapies [12] - Anticipated market shifts with the introduction of next-gen EGFR therapies, creating gaps for MCVO in second and third-line treatments [15][42] Clinical Development Strategy - **Current Studies**: - Two ongoing studies: monotherapy and combination with Pembro, focusing on second-line plus patients [16][17] - Plans for pivotal studies based on emerging data [5][42] Safety Profile - **Safety Observations**: - No grade 4 or 5 adverse events reported; some grade 3 events noted [32][40] - Adjusted ideal body weight dosing strategy being implemented to optimize safety and efficacy [33][34] Future Outlook - **Data Expectations**: - Mature data from the monotherapy study expected in mid-2026, with additional updates on combination therapy [43][56] - Anticipated discussions with the FDA regarding registrational study design, focusing on a randomized approach with control arms [58] Additional Insights - **Patient Demographics**: - Current patient population is heavily weighted towards HPV-positive individuals, with plans to diversify as more expert clinical trial sites are activated [22][23] - **Operational Progress**: - Transitioning from generalist to specialized clinical trial sites has led to increased enrollment efficiency [19][56] This summary encapsulates the critical insights and data shared during the Pyxis Oncology clinical update call, highlighting the company's advancements in treating head and neck cancer with MCVO.

MICVO Monotherapy Efficacy - MICVO monotherapy demonstrated a validated efficacy signal in 2L+ R/M HNSCC, with a 46% confirmed ORR and a 92% DCR (n=13, 5.4 mg/kg)[4] - In the Phase 1 monotherapy dose expansion study at 5.4 mg/kg, Arm 1 (post-PD1/post-Platinum) showed a 60% confirmed ORR (N=5)[32] - Arm 2 (post-PD1/post-EGFRi) in the monotherapy study showed a 25% confirmed ORR (N=4), exceeding the PI benchmark of 20%+[32] - MICVO monotherapy at 5.4 mg/kg demonstrated clear activity with deep responses and exceptional disease control[35] MICVO + KEYTRUDA® Combination Efficacy - MICVO combined with KEYTRUDA® showed a promising emerging efficacy profile in 1L/2L+ R/M HNSCC, with a 71% confirmed ORR and 100% DCR (n=7, 3.6 mg/kg & 4.4 mg/kg)[4] MICVO Safety and Tolerability - MICVO at 5.4 mg/kg in R/M HNSCC showed no Grade 4 or Grade 5 ADC payload TRAEs of interest[40] - Initial data supports a lack of overlapping toxicities observed between MICVO and KEYTRUDA®[52] Market and Clinical Development - FDA aligned on a 2L+ monotherapy pivotal trial design for MICVO[4] - The US R/M HNSCC market is large, growing, and relatively uncrowded, making it ripe for innovation[17] - Projected 2029 US market data shows a significant number of drug-treatable patients, with ~31K in 1L, ~21K in 2L, and ~8K in 3L[18]

Core Insights - Pyxis Oncology announced positive preliminary data from Phase 1 clinical studies of micvotabart pelidotin (MICVO), an antibody-drug conjugate targeting extradomain-B of fibronectin, in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC) [1][2] Monotherapy Findings - In the Phase 1 monotherapy study, MICVO demonstrated a 46% confirmed objective response rate (ORR) and a 92% disease control rate (DCR) at a dose of 5.4 mg/kg in 2L+ R/M HNSCC [4] - The study included 18 patients, all of whom had prior systemic therapy, with a median of 3 prior lines of therapy [5] Combination Therapy Findings - In the Phase 1/2 study combining MICVO with pembrolizumab, the confirmed ORR was 71% and the DCR was 100% at doses of 3.6 mg/kg and 4.4 mg/kg [4][8] - The combination therapy included patients with varying PD(L)-1 CPS scores, and responses were observed even in those who had previously progressed on checkpoint inhibitors [8] Future Developments - Updated data from the ongoing Phase 1 monotherapy study is expected in mid-2026, while updated data from the combination study is anticipated in the second half of 2026 [9] - The company has received FDA alignment on the clinical trial design for a pivotal monotherapy study in 2L+ R/M HNSCC and is evaluating the path forward for pivotal studies [10] Financial Update - Pyxis Oncology completed the sale of rights to royalties from the commercialization of Enzeshu for a one-time cash payment of $11 million, which will support the development of MICVO [11]

Summary of Pyxis Oncology Conference Call Company Overview - **Company**: Pyxis Oncology - **Focus**: ADC (Antibody-Drug Conjugate) development - **Lead Asset**: Novel ADC targeting extracellular domain B (EDB), a splice variant of fibronectin in the tumor microenvironment - **Mechanism**: Extracellular cleaving ADC that kills tumors through direct tumor killing, bystander effect, and immunogenic cell death - **Clinical Development**: Asset brought into the clinic in early 2023, with dose escalation data showing a confirmed overall response rate (ORR) of 50% in head and neck cancer [4][65] Clinical Data and Trials - **Basket Trial**: Conducted with 80 patients across nine tumor types, showing strong tumor regression in head and neck, breast, sarcoma, ovarian, and lung cancers [15][16] - **Efficacious Dose Range**: Identified as 3.6-5.4 mg/kg, with a well-tolerated safety profile [14][15] - **Combination Therapy**: Initiated trials combining the ADC with Pembrolizumab (Pembro) [66] Mechanistic Insights - **Differentiation from Conventional ADCs**: Unlike traditional ADCs that target cell surfaces, Pyxis's ADC cleaves in the extracellular matrix, allowing for direct tumor cell killing [7][8] - **Bystander Effect**: The ADC's mechanism includes a significant bystander effect, which has been validated through translational biology work [9][10] - **Translational Data**: Ten biology and translational posters presented at major conferences, supporting the proof of mechanism for the novel ADC [8][9] Safety and Tolerability - **Adverse Events (AEs)**: Modest AE profile with no grade three treatment-related ocular toxicity or neuropathy; manageable AEs include neutropenia and cutaneous lesions [15][24] - **Comparison with Other ADCs**: Safety profile appears favorable compared to other ADCs, with a stable drug-to-antibody ratio (DAR) of 4 [26][27] Market Position and Strategy - **Head and Neck Cancer**: Identified as an underserved market with significant unmet needs; ongoing trials aim to establish the ADC's role in both current and future treatment paradigms [28][29] - **Monotherapy and Combination Trials**: Two arms in monotherapy targeting platinum and PD-1 resistant patients, and a combination arm with PD-1 inhibitors [30][31] - **Competitive Landscape**: Aiming for an ORR of 35-45% in monotherapy to be competitive, and 60-65% in combination therapy [33][34] Future Directions - **Data Disclosure**: Preliminary data expected by year-end, with insights into market opportunities and regulatory strategies [52] - **Cash Position**: Current cash balance of $77 million, providing runway into the second half of 2026 [54] Additional Insights - **Biomarker Development**: No single biomarker expected to predict response; multiple factors such as protease concentration and tumor matrix characteristics are considered [47] - **Exploration of Other Tumor Types**: Ongoing studies in combination therapy may inform potential applications in other cancers beyond head and neck [48]

Summary of Pyxis Oncology FY Conference Call Company Overview - **Company**: Pyxis Oncology (NasdaqGS:PYXS) - **Lead Asset**: MICVO, an antibody-drug conjugate (ADC) targeting the extracellular domain B (EDB) in solid tumors [4][5] Key Points and Arguments Development Focus - **Target Indication**: Focus on head and neck cancers, with two ongoing programs: monotherapy for second and third line, and combination therapy with Pembrolizumab (Pembro) [5][18] - **Mechanism of Action**: MICVO utilizes a three-pronged mechanism involving direct tumor killing, bystander effect, and immunogenic cell death, allowing for broad applications across various solid tumors [4][12] Clinical Trial Insights - **Phase I Study**: Conducted as a basket dose escalation trial with 80 patients across 10 tumor types, identifying an efficacious dose range of 3.6-5.4 mg/kg [6][7] - **Efficacy Results**: Confirmed response rate of 50% in head and neck cancer patients, with tumor regression observed in six different tumor types [8][15] - **Safety Profile**: Minimal grade three adverse events reported, indicating broad tolerability, particularly in heavily pretreated end-of-life patients [7][10] Competitive Landscape - **Market Positioning**: Aiming to establish a foothold in the head and neck cancer market, competing against other therapies with a focus on both current and emerging treatment lines [16][22] - **Efficacy Expectations**: Minimum expected overall response rate (ORR) of 35% to be considered a credible competitor in the second and third line settings [22][23] Future Development Plans - **Data Updates**: Upcoming data disclosure will include preliminary results from both monotherapy arms and the combination therapy, aimed at shaping the understanding of the competitive landscape [19][20] - **Broader Applications**: While currently focused on head and neck cancers, the mechanism of MICVO suggests potential applications in other solid tumors over time [35][36] Translational Biology Work - **Supporting Mechanism**: Recent translational biology work has validated the mechanism of MICVO, including the identification of key proteases in the tumor microenvironment and T cell activation [12][13][14] Strategic Considerations - **Market Segmentation**: Plans to provide insights on market segmentation and competitive positioning in future updates, considering factors like HPV status and prior treatment history [33][34] Additional Important Insights - **Combination Therapy**: Ongoing combination therapy program with Keytruda, currently in dose escalation phase [18] - **Patient Cohorts**: Distinction between cohorts based on prior treatments (platinum and PD-1 vs. EGFR and PD-1) to assess the agent's efficacy in different treatment lines [16][17] This summary encapsulates the critical aspects of Pyxis Oncology's conference call, highlighting the company's strategic focus, clinical insights, and future development plans in the oncology space.